A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer
- PMID: 28657360
- DOI: 10.1080/03007995.2017.1348344
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer
Abstract
Background: Resistance to endocrine treatment generally occurs over time, especially in the metastatic stage. In this paper, we aimed to review the mechanisms of cyclin-dependent kinase (CDK) 4/6 inhibition and clinical usage of new agents in the light of recent literature updates.
Scope: A literature search was carried out using PubMed, Medline and ASCO and ESMO annual-meeting abstracts by using the following search keywords; "palbociclib", "abemaciclib", "ribociclib", "cyclin-dependent kinase inhibitors" and "CDK 4/6" in metastatic breast cancer (MBC). The last search was on 10 June 2017.
Findings: CDKs and cyclins are two molecules that have a key role in cell cycle progression. Today, there are three highly selective CDK4/6 inhibitors in clinical development - palbociclib, ribociclib and abemaciclib. Palbociclib and ribociclib were recently approved by the US FDA in combination with letrozole for the treatment of MBC in a first-line setting, as well as palbociclib in combination with fulvestrant for hormone-receptor (HR)-positive MBC that had progressed while on previous endocrine therapy according to the PALOMA-1, MONALEESA-2 and PALOMA-3 trials, respectively. In the recently published randomized phase III MONARCH 2 trial, abemaciclib plus letrozole had longer progression-free survival and higher objective response rates with less serious adverse events in advanced HR-positive breast cancer previously treated with hormonal treatment.
Conclusion: CDK4/6 inhibition is a new and promising target for patients with hormone-receptor-positive MBC. Both palbociclib and ribociclib showed significant additive benefit for patients receiving first-line treatment for HR-positive, epidermal growth factor receptor-2-negative advanced breast cancer. Palbociclib and abemaciclib also had significant activity in combination with fulvestrant for patients with MBC that progressed on previous endocrine therapy.
Keywords: Metastatic breast cancer; abemaciclib; cyclin-dependent kinase inhibitors; palbociclib; ribociclib.
Similar articles
-
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.Am J Health Syst Pharm. 2019 Aug 1;76(16):1183-1202. doi: 10.1093/ajhp/zxz121. Am J Health Syst Pharm. 2019. PMID: 31369120 Review.
-
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.BioDrugs. 2019 Apr;33(2):125-135. doi: 10.1007/s40259-019-00337-6. BioDrugs. 2019. PMID: 30847853 Review.
-
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.Ann Pharmacother. 2015 Nov;49(11):1252-60. doi: 10.1177/1060028015602273. Epub 2015 Aug 31. Ann Pharmacother. 2015. PMID: 26324355 Free PMC article. Review.
-
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.Breast Cancer Res Treat. 2017 Nov;166(1):41-54. doi: 10.1007/s10549-017-4385-3. Epub 2017 Jul 24. Breast Cancer Res Treat. 2017. PMID: 28741274 Review.
-
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.Jpn J Clin Oncol. 2019 Dec 18;49(11):993-998. doi: 10.1093/jjco/hyz151. Jpn J Clin Oncol. 2019. PMID: 31665472 Review.
Cited by
-
Piperazine ring toxicity in three novel anti-breast cancer drugs: an in silico and in vitro metabolic bioactivation approach using olaparib as a case study.Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396(7):1435-1450. doi: 10.1007/s00210-023-02413-9. Epub 2023 Feb 4. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 36738368
-
CDK4/6 inhibitors in lung cancer: current practice and future directions.Eur Respir Rev. 2024 Feb 14;33(171):230145. doi: 10.1183/16000617.0145-2023. Print 2024 Jan 31. Eur Respir Rev. 2024. PMID: 38355149 Free PMC article. Review.
-
Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LC-MS/MS: in vitro metabolic investigation.R Soc Open Sci. 2019 Jan 23;6(1):181714. doi: 10.1098/rsos.181714. eCollection 2019 Jan. R Soc Open Sci. 2019. PMID: 30800400 Free PMC article.
-
Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models.Cancer Genomics Proteomics. 2020 Jul-Aug;17(4):321-334. doi: 10.21873/cgp.20192. Cancer Genomics Proteomics. 2020. PMID: 32576578 Free PMC article. Review.
-
Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC.Front Oncol. 2021 Jul 30;11:676041. doi: 10.3389/fonc.2021.676041. eCollection 2021. Front Oncol. 2021. PMID: 34395246 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials